- 作者：Luis A. Kluth ; Evanguelos Xylinas ; Malte Rieken ; Felix K.-H. Chun ; Harun Fajkovic ; Andreas Becker ; Pierre I. Karakiewicz ; Niccolo Passoni ; Michael Herman ; Yair Lotan ; Christian Seitz ; Paul Schramek ; Mesut Remzi ; Wolfgang Loidl ; Bertr ; Guillonneau ; Morgan Roupr锚t ; Alberto Briganti ; Douglas S. Scherr ; Markus Graefen ; Ashutosh K. Tewari ; et al.
- 关键词：Prostate cancer ; Pelvic lymph node dissection ; Lymph node metastasis ; Nodal yield ; Biochemical recurrence
- 刊名：Urologic Oncology: Seminars and Original Investigations
- 出版年：January, 2014
- 年：2014
- 卷：32
- 期：1
- 页码：47.e1-47.e8
- 全文大小：744 K
Objectives
To determine if the number of lymph nodes (LNs) removed is an independent predictor of biochemical recurrence (BCR) in patients without LN metastases undergoing radical prostatectomy (RP).Material and methods
Retrospective analysis of 7,310 patients treated at 7 centers with RP and pelvic LN dissection for clinically localized prostate cancer between 2000 and 2011. Patients with LN metastases (n = 398) and other reasons (stated later in the article) (n = 372) were excluded, which left 6,540 patients for the final analyses.
Results
Overall, median biopsy and RP Gleason score were both 7; median prostate specific antigen level was 6 ng/ml (interquartile range [IQR]: 5); and median number of LNs removed was 6 (IQR: 8). A total of 3,698 (57%), 2,064 (32%), and 508 (8%) patients had 鈮?, 鈮?0, and 鈮?0 LNs removed, respectively. Patients with more LNs removed were older, had a higher prostate specific antigen level, had higher clinical and pathologic T stage, and had higher RP Gleason score (all P<0.002). Within a median follow-up of 21 (IQR: 16) months, more LNs removed was associated with an increased risk of BCR (continuous: P = 0.021; categorical: P = 0.014). In multivariable analyses that adjusted for the effects of standard clinicopathologic factors, none of the nodal stratifications predicted BCR.
Conclusions
The number of LNs did not have any prognostic significance in our contemporary cohort of patients with LN-negative prostate cancer. This suggests that the risk of missed clinically significant micrometastasis may be minimal in patients currently treated with RP and having a lower LN yield.